# US 10,864,212 B2 · Compositions and methods for treating retinal degradation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,212 B2
- Document ID: US10864212B2
- Status: Granted
- Kind: B2
- Application number: 16/361,810
- Filed: 2019-03-22
- Published: 2019-08-22
- Granted: 2020-12-15
- Earliest claimed: 2013-08-01
- Assignees: University of Kentucky Research Foundation
- Applicants: University of Kentucky Research Foundation
- Inventors: Jayakrishna Ambati; Benjamin Fowler
- Web page: https://patentgrep.com/patent/US10864212B2

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 411/04: directly linked by a ring-member-to-ring-member bond
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.

## Claims

### Claim 1

A method of treating a condition selected from Parkinson's disease, Alzheimer's disease, and multiple sclerosis comprising administering to a subject in need thereof a compound selected from:
(i) a compound having the structure of formula I
or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of formula II
(iii) a compound having the structure of formula III, or a pharmaceutically acceptable salt thereof;
(iv) a compound having the structure of formula IV,
wherein n is 10 to 20;
(v) a compound having the structure of formula V
(vi) stavudine (d4T);
(vii) lamivudine (3TC);
(viii) cordycepin;
(ix) azidothymidine (AZT);
(x) abacavir (ABC); and
(xi) a combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is selected from:
(i) the compound having the structure of formula I
or a pharmaceutically acceptable salt thereof;
(ii) the compound having the structure of formula II
(iii) the compound having the structure of formula III, or a pharmaceutically acceptable salt thereof;
(iv) the compound having the structure of formula IV,
wherein n is 10 to 20;
(v) a compound having the structure of formula V
(vi) a combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein n is 11.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is selected from:
(i) the compound having the structure of formula
or a pharmaceutically acceptable salt thereof;
(ii) the compound having the structure of formula II
and
(iii) a compound having the structure of formula V
and
(iv) a combination thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is selected from:
(i) the compound having the structure of formula
or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of formula V
and
(iii) a combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound is a compound having the structure of formula I
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound is the compound having the structure of formula II:

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound is the compound having the structure of formula V:

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound is selected from
(vi) stavudine (d4T);
(vii) lamivudine (3TC);
(viii) cordycepin;
(ix) azidothymidine (AZT);
(x) abacavir (ABC); and
(xi) a combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method comprises administering a composition comprising the compound and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1)

The method of claim 1, wherein the condition is Parkinson's disease.

### Claim 12 (depends on 1)

The method of claim 1, wherein the condition is Alzheimer's disease.

### Claim 13 (depends on 1)

The method of claim 1, wherein the condition is multiple sclerosis.